As most everyone already knows by now, TKK Symphony (TKKS) announced earlier that it would be extending the expiration of it’s tender offer. The tender offer was expected to expire tonight (at one minute past 11:59PM), but will now expire at 5:00 p.m. New York City time, on Monday, December 2, 2019. Keep in mind that TKKS does not run out its SPAC deadline until February 20, 2020, so there could be an additional extension of the tender offer after December 2nd.
Interestingly, only 12,210,031 of the 25,000,000 TKKS shares available have been tendered to-date, or roughly 50%. However, leading up to today’s tender expiration, the share price had traded down significantly, closing yesterday at $6.17, after trading as low as $5.50. So, presumably, TKKS is going to use the next two weeks for additional marketing to generate much needed demand.
However, given that approximately $125 million of the trust that still hadn’t tendered as of this morning (12.2 million shares x $10.26 per share), and the share price was in the low sixes, did those remaining shareholders want to own the share? Or, were they waiting until the end of the day to tender? OR, although unlikely given the sheer size of $125 million, did they just not understand the tender offer process and that was simply a mistake? Perhaps a little bit of all three, but it’s interesting that TKKS would not want to close this tender offer TODAY and keep that $125 million. Instead, now those 12.2 million shares that haven’t tendered yet have a little more than two weeks to do so, further depleting the trust. So it’s a bit of a mystery what’s really going on here. Plus, there is always the possibility that TKKS will now use the additional time to round up a quick backstop.
Something else to consider is that TKK Symphony’s Unit has a Right. So even if they do get a backstop, there will be 2.5 million Rights Shares looking to sell post-close and based on yesterday’s share price, it will be difficult to generate enough demand to counteract that selling pressure. As a result, any backstops will need to be done at a price significantly below $10.00.
Let’s see what happens, but for now, there are still a lot of question marks. Stay tuned.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...